Home／Products & Technology／Pipeline
R&D PIPELINE · RADIOPHARMACEUTICALS
12 R&D Programs Spanning
6 Therapeutic Areas
From eight marketed TFDA-approved drug licenses to a diversified radionuclide portfolio in neurology, oncology, and the new Miaoli facility — PET Pharm Bio's R&D pipeline spans both diagnostics and therapeutics, representing the most complete pipeline among Taiwan's private radiopharmaceutical companies.
APPROVED & MARKETED
Approved & Marketed Products
PET Pharm Bio currently holds 8 TFDA-approved drug licenses.
18F-FDG Fludeoxyglucose
License R00033 / R00043 / R00045 / R00050
Cancer metabolic PET imaging; routine supply to nuclear medicine centers nationwide
APPROVED
18F-FBB Neuraceq
License R00036
Alzheimer's disease Aβ imaging. Dual production sites in Taipei/Luzhu provide the industry's most stable supply.
APPROVED
18F-NaF Sodium Fluoride
License R00040 / R00042
Early detection imaging of bone metastasis, superior to conventional bone scans
APPROVED
131I Sodium Iodide Capsules
License R00034
Post-surgical thyroid remnant ablation and diagnostic scanning for thyroid cancer
APPROVED
THERANOSTICS PIPELINE
177Lu, 161Tb, 64Cu /67Cu, 225Ac —
Taiwan's Only Four-Nuclide Therapeutic Radiopharmaceutical Portfolio
PET Pharm Bio is the only private radiopharmaceutical company in Taiwan simultaneously developing four therapeutic isotopes: 177Lu, 161Tb, 64Cu /67Cu, and 225Ac.
177Lu
NPM
PSMA I&T · Prostate Cancer (mCRPC)
Targeted Radiotherapy
Targeted Radiotherapy
161Tb
Clinical Trial
PSMA I&T · Prostate Cancer (mCRPC)
Next-Gen Targeted Therapy Nuclide
Next-Gen Targeted Therapy Nuclide
64Cu /67Cu
In Development
Cancer
Theranostics
Theranostics
225Ac
In Development
Cancer Alpha Therapy
New Nuclide Program
New Nuclide Program
89Zr
In Development
Antibody / Cell Therapy Drugs
PET Precision Diagnosis
PET Precision Diagnosis
68Ga
In Development
Peptide-Based Cancer Therapy (Pre-Treatment)
PET Precision Diagnosis
PET Precision Diagnosis
Proprietary R&D Pipeline
PET Pharm Bio R&D Programs
PET Pharm Bio's Uncontested Blue Ocean — Parkinson's Disease Imaging
FP-CIT (DAT-targeted) and AV-133 (VMAT2-targeted) are currently the only Parkinson's disease precision imaging diagnostic programs among Taiwan's local private radiopharmaceutical companies. As Taiwan's population ages, demand for precise Parkinson's disease diagnosis continues to grow, giving this drug series a significant first-mover advantage.
| Candidate | Molecular Profile | Clinical Progression |
|---|---|---|
| Diagnosis [18F] FP-CIT PPhB-F03 |
Parkinson's Disease Target: DAT | Isotope: 18F |
Pre-Clin.Phase 1 Phase 2 Phase 3Reg. Filing
|
| Diagnosis [18F] AV-133 PPhB-F04 |
Parkinson's Disease Target: VMAT2 | Isotope: 18F |
Pre-Clin.Phase 1 Phase 2 Phase 3Reg. Filing
|
Partnership & CDMO Services
Partnership / CDMO Programs
| Candidate | Molecular Profile | Clinical Progression |
|---|---|---|
| Therapy [161Tb] PSMA I&T PPhB-Tb01 |
Prostate Cancer (mCRPC) Target: PSMA | Isotope: 161Tb |
Pre-Clin. Phase 1 Phase 2 Phase 3Reg. Filing
|
| Diagnosis [18F] FBPA PPhB-F01 |
Brain Cancer / Osteosarcoma Target: LAT | Isotope: 18F |
Pre-Clin. Phase 1 Phase 2 Phase 3Reg. Filing
|
| ---- Honeybear / HB001 |
Pre-Clin. Phase 1 Phase 2 Phase 3Reg. Filing
|
Named Patient Manufacture (NPM)
Named Patient Manufacture
| Candidate | Molecular Profile | Clinical Progression |
|---|---|---|
| Therapy [177Lu] PSMA I&T PPhB-Lu01 |
Prostate Cancer (mCRPC) Target: PSMA | Isotope: 177Lu |
Pre-Clin. Phase 1 Phase 2 Phase 3Reg. Filing
|
NUCLIDE R&D PIPELINE
Medical Nuclide Development
| Isotope / Half-life | Application Area | Development Phase |
|---|---|---|
| New Nuclide R&D 64Cu / 67Cu 12.7 hrs / 61.83 hrs |
Cancer Theranostics (Dx + Tx) |
In Development In Production DMF
|
| New Nuclide R&D 225Ac 9.92 days |
Cancer / RPTTargeted Alpha Therapy |
In Development In Production DMF
|
| New Nuclide R&D 89Zr 78.4 hrs |
Antibody / Cell Therapy Drugs PET Precision Diagnosis |
In Development In Production DMF
|
| New Nuclide R&D 68Ga 68 min |
Cancer Peptide-Based Cancer Therapy (Pre-Treatment) PET Precision Diagnosis |
In DevelopmentIn Production DMF
|